- June 6, 2018 – BioSpace.com – Pfizer Adds $600 Million to Venture Arm with 25% Slated for Neuroscience
- May 23, 2018 – Providence Business News – MindImmune Therapeutics agrees to acquire two programs from H. Lundbeck
- May 23, 2018 – MedWatch – Lundbeck sells preclinical drugs to former research exec
- May 22, 2018 – ConvergenceRI – The MindImmune research enterprise lifts off
- May 22, 2018 – Lundbeck – Lundbeck divests preclinical research programs
- February 23, 2018 – AmericanInno.com – MindImmune Using a Different Strategy to Cure Alzheimer’s
- February 9, 2018 – AmmericanInno.com – MindImmune wins “Inno Blazer” for Health/Wellness at RI “50 on Fire” awards event.
- December 17, 2017 – AmericanInno.com – MindImmune named in inaugural “50 on Fire” early-stage businesses in RI.
- January 23, 2018 – Providence Journal – URI-based MindImmune Agrees to Pact with Drug Giant Pfizer
- January 22, 2018 – ConvergenceRI – Pfizer Backs Research Platform of MindImmune
- August 21, 2017 – Providence Business News – MindImmune closes $500K seed round
- August 21, 2017 – ConvergenceRI – Pioneering a new approach to treatment of brain disease
- November 22, 2016 – Providence Business News – Innovation Vouchers awarded to six companies by Commerce RI
- November 22, 2016 – Providence Journal – RI Commerce Corp funds programs
- July 18, 2016 – ConvergenceRI – To go where no research enterprise has gone before in Rhode Island
- July 14, 2016 – Providence Business News – Slater Technology Fund invests $500K in MindImmune Therapeutics
- July 14, 2016 – Providence Journal – Slater Fund offers $500,000 for new drug-discovery firm
- July 14, 2016 – URI Today – Slater Commits Seed Funding to MindImmune Therapeutics, Drug Discovery Venture Targeting Neuro-Degenerative Disease
- May 30, 2016 – ConvergenceRI – MindImmune, a promising new drug development firm, develops its RI roots
- April 7, 2016 – Providence Journal – Neuroscience startup at URI to focus on Alzheimer’s, Parkinson’s